Ensign Peak Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-126,625
| Closed | -$12.9M | – | 1782 |
|
|
2023
Q2 | $12.9M | Buy |
126,625
+8,250
| +7% | +$841K | 0.03% | 361 |
|
|
2023
Q1 | $10.8M | Buy |
118,375
+47,460
| +67% | +$4.32M | 0.02% | 396 |
|
|
2022
Q4 | $2.69M | Sell |
70,915
-7,200
| -9% | -$274K | 0.01% | 723 |
|
|
2022
Q3 | $1.96M | Buy |
78,115
+15,379
| +25% | +$386K | ﹤0.01% | 790 |
|
|
2022
Q2 | $1.91M | Buy |
62,736
+41,309
| +193% | +$1.26M | ﹤0.01% | 823 |
|
|
2022
Q1 | $702K | Buy |
21,427
+14,847
| +226% | +$486K | ﹤0.01% | 1405 |
|
|
2021
Q4 | $174K | Buy |
+6,580
| New | +$174K | ﹤0.01% | 1953 |
|
|
2021
Q3 | – | Sell |
-11,218
| Closed | -$1.59M | – | 1888 |
|
|
2021
Q2 | $1.59M | Buy |
11,218
+8,947
| +394% | +$1.27M | ﹤0.01% | 1240 |
|
|
2021
Q1 | $226K | Hold |
2,271
| – | – | ﹤0.01% | 1715 |
|
|
2020
Q4 | $281K | Sell |
2,271
-7,372
| -76% | -$912K | ﹤0.01% | 1684 |
|
|
2020
Q3 | $939K | Buy |
9,643
+6,759
| +234% | +$658K | ﹤0.01% | 1337 |
|
|
2020
Q2 | $450K | Buy |
2,884
+560
| +24% | +$87.4K | ﹤0.01% | 1484 |
|
|
2020
Q1 | $335K | Sell |
2,324
-690
| -23% | -$99.5K | ﹤0.01% | 1467 |
|
|
2019
Q4 | $617K | Buy |
+3,014
| New | +$617K | ﹤0.01% | 1483 |
|